These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2515092)

  • 1. [Conditions for obtaining hemostatic preparations from donor plasma].
    Kunakova NV; Diakonova SF; Rusanov VM; Rudnitskaia MZ
    Gematol Transfuziol; 1989 Oct; 34(10):40-2. PubMed ID: 2515092
    [No Abstract]   [Full Text] [Related]  

  • 2. Clotting factor concentrates.
    Entwistle CC
    Int Anesthesiol Clin; 1985; 23(2):49-59. PubMed ID: 3924836
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of chromatography to manufacture purer and safer plasma products.
    Johnston A; Adcock W
    Biotechnol Genet Eng Rev; 2000; 17():37-70. PubMed ID: 11255674
    [No Abstract]   [Full Text] [Related]  

  • 4. [Technic of obtaining the antihemophilic factors VIII and IX and their clinical application].
    Triginer J; Vila M; Vicente Arangüena P
    Sangre (Barc); 1979; 24(5-C):937-41. PubMed ID: 121169
    [No Abstract]   [Full Text] [Related]  

  • 5. Recommendations of the subcommittee on human factor VIII (AHF) and factor IX (PTC) preparations.
    Wagner RH
    Thromb Diath Haemorrh Suppl; 1968; 35():235-7. PubMed ID: 5761065
    [No Abstract]   [Full Text] [Related]  

  • 6. Whole blood collection using metered anticoagulation for production of Factor VIII and Factor IX.
    Penny A; Pinner M; Townley A; Mosley P; Smith J; Lane R; Munford C; Robinson A
    Prog Clin Biol Res; 1990; 337():487-9. PubMed ID: 2112756
    [No Abstract]   [Full Text] [Related]  

  • 7. Simultaneous collection of platelets and cryoprecipitate by plasma-exchange donation.
    McLeod BC; Sassetti RJ; Owens EA; Scott JP
    Transfusion; 1989 May; 29(4):332-6. PubMed ID: 2497567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A therapeutic concentrate of coagulation factors II, IX and X from citrated, factor VIII-depleted plasma.
    Middleton SM; Bennett IH; Smith JK
    Vox Sang; 1973 May; 24(5):441-56. PubMed ID: 4691239
    [No Abstract]   [Full Text] [Related]  

  • 9. Plasma exchange donation of cryoprecipitate after DDAVP stimulation: an alternative source of factor VIII.
    McLeod BC; Scott JP
    Prog Clin Biol Res; 1990; 324():189-98. PubMed ID: 2106687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Isolation of blood coagulation factors (VII, VIII and IX)].
    Dzegilenko NB
    Gematol Transfuziol; 1990 May; 35(5):38-40. PubMed ID: 2118467
    [No Abstract]   [Full Text] [Related]  

  • 11. The current status of blood fractionation in the United States.
    Sgouris JT
    Vox Sang; 1972; 23(1):45-55. PubMed ID: 5081014
    [No Abstract]   [Full Text] [Related]  

  • 12. [Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
    Ikematsu S; Yorifuji H; Arai M; Fukutake K
    Rinsho Ketsueki; 1988 May; 29(5):628-34. PubMed ID: 3145993
    [No Abstract]   [Full Text] [Related]  

  • 13. Heat inactivation of human immunodeficiency virus in lyophilized factor VIII and factor IX concentrates.
    Piszkiewicz D; Bourret L; Lieu M; Hattley K; Thomas W; Cabradilla CD; Kingdon H; Menache D
    Thromb Res; 1987 Jul; 47(2):235-41. PubMed ID: 3116716
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma fractionation in blood transfusion service.
    Haskó F; Salamon M; Bartha K; Dobó P
    Dev Biol Stand; 1987; 67():39-48. PubMed ID: 3111912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Affinity chromatography of coagulation factors II, VIII, IX and X on matrix-bound phospholipid vesicles.
    Andersson LO; Thuy LP; Brown JE
    Thromb Res; 1981 Sep; 23(6):481-9. PubMed ID: 6798706
    [No Abstract]   [Full Text] [Related]  

  • 16. Is the poor recovery of commercial recombinant factors VIII and IX caused by damage from monoclonal antibody purification?
    Shanbrom E
    Thromb Haemost; 2002 Oct; 88(4):700. PubMed ID: 12362253
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatitis C and pasteurised factor VIII and IX concentrates.
    Klarmann D; Kreuz W; Auerswald G; Auberger K; Rabenau H; Gürtler L; Roggendorf M
    Thromb Haemost; 1995 Apr; 73(4):736-7. PubMed ID: 7495095
    [No Abstract]   [Full Text] [Related]  

  • 18. Polyvinylpyrrolidone (PVP): a new precipitating agent for human and bovine factor VIII and fibrinogen.
    Casillas G; Simonetti C
    Br J Haematol; 1982 Apr; 50(4):665-72. PubMed ID: 6802165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outbreaks of hepatitis A and emergence of new AIDS-associated agents: the need to add terminal 100 degrees C dry-heat sterilization to factor VIII and factor IX concentrates.
    Guillaume TA
    Vox Sang; 1993; 65(2):158. PubMed ID: 8212671
    [No Abstract]   [Full Text] [Related]  

  • 20. Plasma fractionation in the United States. A review for clinicians.
    Ness PM; Pennington RM
    JAMA; 1974 Oct; 230(2):247-50. PubMed ID: 4137885
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.